Neoprobe, XTL deal

The companies signed a letter of intent for an investment and technology option agreement. In return for funding research at XTL, NEOP has an exclusive right to license XTL’s Trimera technology for use in NEOP’s ACT cancer therapy and for producing human monoclonal antibodies for NEOP’s RIGS cancer detection system.

Trimera is a technology that enables development of human monoclonal antibodies in mice as well as providing a tool for modeling human diseases (see Emerging Company Profile, BioCentury Sept. 25, 1995) ...